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Dimethylfumarate Reduces Leukocyte Rolling in Vivo
through Modulation of Adhesion Molecule Expression
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and Wolf-Henning Boehncke1
Esters of fumaric acid have a long tradition in the treatment of psoriasis. Dimethylfumarate (DMF) is perceived
as the main active substance. However, the molecular mechanisms of DMF action are not completely
understood. Here, we investigate the effects of DMF on lymphocyte adhesion molecule expression in vitro and
interactions with endothelial cells in vivo. DMF dose-dependently reduced superantigen-induced expression of
CD25, human leukocyte antigen-DR, and cutaneous lymphocyte antigen by 27, 22, and 48% on CD3-positive
cells, respectively. No change was observed for CD54, VLA-4, and P-selectin glycoprotein ligand-1. An
enhancement of CD69 expression was noted (22%). DMF led to a significant reduction in binding of human
peripheral blood mononuclear cells (PBMCs) to E-selectin (72%), P-selectin (36%), and vascular cell adhesion
molecule-1 (33%) in vitro. Intravital microscopy of PBMCs in ear vasculature of wild-type and knockout mice
showed that rolling was mainly P-selectin-dependent and could be reduced by 61% through DMF incubation.
We provide early evidence that DMF affects adhesion molecule expression on human leukocytes and their
rolling behavior in vivo, indicating that DMF directly affects the initial step of leukocyte extravasation.
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INTRODUCTION
Leukocyte extravasation from the bloodstream into tissues is a
central pathophysiological feature of chronic inflammatory
diseases. It is initiated by interactions between selectin
adhesion molecules (E-, L-, and P-selectins) and their ligands
(cutaneous lymphocyte antigen (CLA) and P-selectin glyco-
protein ligand-1 (PSGL-1)) resulting in tethering and rolling
along postcapillary venules. Immediately, chemokines trigger
increased leukocyte integrin avidity allowing them to firmly
adhere to the endothelium (Butcher and Picker, 1996; Scho¨n
and Ludwig, 2005). Firm adhesion is mediated by inter-
actions between members of the integrin family of adhesion
molecules (e.g., very late antigen-4 (VLA-4)) and of the
immunoglobulin family of adhesion molecules (e.g., VCAM-1).
Adherent leukocytes finally migrate into the neighboring
tissue. Inflammatory skin diseases, such as psoriasis, are
associated with the epidermal and dermal accumulation of
lymphocytes (Krueger, 1998; Bovenschen et al., 2005; Scho¨n
and Boehncke, 2005). Blocking the generation of an
inflammatory infiltrate by interfering with key molecules of
the extravasation process is an attractive strategy to treat
inflammation (Boehncke and Scho¨n, 2003); numerous
approved drugs, such as Raptiva, use this approach (Nicolls
and Gill, 2006).
For decades, fumaric acid esters have been successfully
used to treat psoriasis. Dimethylfumarate (DMF), as the active
compound among these esters, is known to be a potent
inducer of apoptosis at concentrations beyond 10 mg/ml
(Treumer et al., 2003). In keratinocytes, DMF has been
shown to have an antiproliferative effect, which might be
linked to a transient [Ca2þ ] elevation. In addition, DMF
inhibits proliferation (Thio et al., 1994) and prevents
differentiation of monocytes into dendritic cells (Zhu and
Mrowietz, 2001). Further studies showed that DMF switches
the T-cell response toward a Th2 cytokine profile (Ockenfels
et al., 1998), leading to a reduction in cytotoxic and T-helper
cells (Sebo¨k and Schneider, 2000), and interferes with the
cellular glutathione metabolism (Nelson et al., 1999;
Lehmann et al., 2007). Hence, from this research, it seems
that the anti-inflammatory effects are mediated by a sum of
actions rather than a single specific effect. We here provide
further evidence for this assumption, reporting that DMF
dose-dependently affects the surface expression of different
activation markers and adhesion molecules as well as E- and
P-selectin binding to CD3-positive leukocytes, consequently
reducing in vivo rolling of human peripheral blood mono-
nuclear cells (PBMCs) along the mouse ear vasculature.
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RESULTS
DMF inhibits TSST-1-induced expression of activation markers
and adhesion molecules in vitro
Inflammatory skin diseases are associated with an upregula-
tion of endothelial cell adhesion molecules, and the
infiltration of inflammatory cells is an important feature in
the pathogenesis of psoriasis (Zollner et al., 2002; Zollner and
Asadullah, 2003). Bacterial superantigens, such as toxic
shock syndrome toxin-1 (TSST-1), belong to the strongest
T-cell-activating compounds and are involved in the induc-
tion of psoriasis (Leung et al., 1995; Boehncke et al., 1996,
1997). We therefore investigated the effect of DMF on
superantigen-induced adhesion molecule expression on
human CD3-positive T cells.
To analyze the effects of DMF on different surface
molecules on these cells, we stimulated them with TSST-1
for 96 hours. Our group has previously shown that a time
span of 96 hours resulted in significant expression changes of
several surface molecules comparing TSST-1-stimulated and
unstimulated CD3-positive T cells (Zollner et al., 2002).
Using flow cytometry, we confirmed that stimulation of these
cells with TSST-1 led to an enhanced surface expression of
early and late activation markers, adhesion molecules (Figure
1a and b), and selectin ligands (Figure 1c). Basic expression
values from unstimulated cells regarding the expression of
CD25, CD69, HLA-DR, and CD54 in lymphocyte-sized CD3-
positive T cells were 11.4, 12.1, 19.8, and 41.3%,
respectively, compared with TSST-1-treated cells used as
positive controls, and values were set at 100%.
Pre-treatment of cells with different non-toxic concentra-
tions of DMF before activation led to a significant and dose-
dependent reduction of early activation marker CD25 from
100 to 73% and of late activation marker HLA-DR from 100
to 77.7% on CD3-positive T cells. Furthermore, DMF
treatment resulted in an elevation of CD69 expression to
121.8% compared to TSST-1 stimulation. The effect of DMF
on adhesion molecule expression varied: expression of the
skin-homing receptor CLA was threefold increased by TSST-1
and dose-dependently reduced by increasing concentrations
of DMF, reaching a maximal reduction to around 50% at
5 mg/ml DMF. TSST-1 stimulation increased CD54 expression
by 55%, PSGL-1 expression by 17%, and VLA-4 expression
by 7%, whereas no significant changes were detected for
these molecules after DMF treatment. These findings are
summarized in Table 1. Alterations in expression were not
due to toxicity of DMF, as propidium iodide staining was
always included (Figure S1).
In vitro binding of soluble adhesion molecules to leukocytes
is impaired after DMF stimulation
To test the functional consequences of DMF stimulation,
binding assays to important adhesion molecules, including
E-selectin, P-selectin, and VCAM-1, were performed using
chimeric fusion proteins (Figure 1c). Results are expressed in
comparison to TSST-1-stimulated cells without any manipu-
lation; this value was set at 100%. TSST-1 stimulation
increased binding to E-selectin, P-selectin, and VCAM-1
from 18.3, 77, and 69.2%, respectively, to 100%. Binding to
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Figure 1. (a and b) Representatitive expression patterns of different activation markers, adhesion molecules, and ligands on human PBMCs after
DMF-treatment. (c) Effects of DMF on E- and P-selectin binding. Human PBMCs were isolated from buffy coats using Ficoll–Hypaque density gradient
sedimentation. Cells were either left unstimulated, stimulated with TSST-1 (50 ng/ml), or treated with TSST-1 plus DMF (5 mg/ml). After 96 hours, surface
expression of indicated activation markers, adhesion molecules, or ligands on CD3-positive cells was analyzed via flow cytometry, gating on lymphocyte-sized
T cells. (a) Histogram plots showing the effects of stimulation on expression of CD25, CD69, HLA-DR, and ICAM-1 (CD54). (b) Histogram plots showing these
effects on expression of CLA. (c) DMF influence on E- and P-selectin binding. Numbers in the upper right quadrants of the plot represent the mean values of
fluorescence intensity obtained for each marker. The arrows indicate fluorescence intensity of CD3þ T cells and/or different surface molecules. Significant
reduction or elevation by DMF (5.0 mg/ml) is indicated with * (nX6, Po0.05).
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E-selectin was strongly reduced to 84% at the low concen-
tration of 0.1 mg/ml DMF and was further decreased by
increasing concentrations of DMF to 28.3%. Initial concen-
trations of DMF (0.1 and 1.0 mg/ml) had no significant effect
on P-selectin binding, whereas higher concentrations (2.5
and 5.0 mg/ml) significantly reduced binding to P-selectin
down to 64%. Binding to VCAM-1 was reduced to 68%. The
statistical summary of expression patterns is given in Table 1.
Decreased rolling interactions of DMF-treated PBMCs with
postcapillary venules
Next, we analyzed the rolling behavior of DMF-treated
PBMCs in vivo by means of intravital microscopy. A catheter
was set into the carotid artery of an anesthetized C57Bl/6
(wild-type (wt)) mouse, differentially treated cells were
injected, and rolling interaction of these cells was analyzed.
Basal rolling interactions were determined by injecting
unstimulated cells. Compared to these cells (rolling fraction
(rf): 11.9%), a 61% increase in rolling behavior of TSST-1-
stimulated cells (rf: 19.45%) was observed (Figure 2). Pre-
treatment of TSST-1-activated human PBMCs with 5.0 mg/ml
DMF resulted in reduced rolling interactions comparable to
basal levels (11.9%). Since DMF was administered only to
PBMCs, before injection into the mice, its effects on
endothelial cells could not influence the observation.
Reduction in rolling behavior in vivo is P-selectin-dependent
To address whether decreased rolling behavior of DMF-
treated cells is E- and/or P-selectin-dependent, we performed
similar intravital microscopy in P-selectin-deficient (P/)
mice. Rolling of TSST-1-stimulated cells was significantly
reduced in P/ mice (9.0%) compared with wt mice
(19.4%, P¼ 0.007), confirming that P-selectin plays a major
role in leukocyte rolling. TSST-1 stimulation plus DMF had
no significant effect on rolling interactions in P/ mice
compared with wt mice (8.3%, P¼0.36). Finally, antibody
blockade of E-selectin in P/ mice did not further affect
rolling interactions (6.0%, Figure 2).
Table 1. Statistical summary of DMF effects on all molecules analyzed
Stimulation
— TSST-1 TSST-1 TSST-1 TSST-1 TSST-1
Treatment
Parameter n — 0.1 lg/ml DMF 1lg/ml DMF 2.5lg/ml DMF 5 lg/ml DMF
CD25 5 13.772 100 99.671.5 95.173 82.275 7377*
CD69 4 25.676.6 100 99.973 1 03.6712 103.378.3 121.8714.3*
HLA-DR 4 32.874.8 100 99.472.7 82.678.7 76.376.8 77.777.4*
CD54 4 44.577.2 100 102.771.6 101.972.4 98.671.7 102.873.2
CLA 8 3275 100 96.470.5 91.173 6777.6 5278.6*
PSGL-1 5 83.372.6 100 9574 99.772.7 102.572.2 9772.3
VLA-4 4 92.372.3 100 10070.4 99.370.5 97.771.7 96.171.9
E-selectin binding 5 18.373 100 83.874.6 83.377 52.574.6 28.372.7*
P-selectin binding 5 76.974.8 100 95.579.6 88.578.8 70.977 63.678.1*
VCAM binding 8 60.9714.3 100 102.5720 77.6712.8 79.2710.7 68.5710.1*
DMF, dimethylfumarate; PSGL-1, P-selectin glycoprotein ligand-1; TSST-1, toxic shock syndrome toxin-1; VCAM, vascular cell adhesion molecule.
Summary of TSST-1 and DMF effects on all molecules investigated. DMF concentrations used were 0.1; 1.0; 2.5 and 5.0mg/ml. TSST-1-stimulation led to a
significant increase in expression/binding in all experiments. To compare treatment groups, TSST-1 values were normalized to 100% and sample values were
given as percentage. Statistical significance was determined using ANOVA multiple comparisons and Bonferroni procedure.
*Po0.05, compared to TSST-1 stimulation.
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Figure 2. DMF reduces the rolling of human PBMCs in mouse ear
vasculature. Using intravital microscopy of mouse ear vasculature, we
compared the rolling behavior of untreated, TSST-1-stimulated (50 ng/ml),
and TSST-1 plus DMF-treated (5 mg/ml) human PBMCs in wt and P-selectin-
deficient (P/) mice. Human PBMCs were isolated and treated as described
under Materials and Methods. Basal rolling interactions were analyzed in wt
mice by injecting unstimulated cells. After small injections of NaCl
TSST-1-stimulated or DMF-treated cells were injected, and rolling behavior
was analyzed. Additionally, in P/ mice control IgG or an anti-E-selectin
antibody was injected before cell injection. Interactions of cells with the
vasculature were recorded via video documentation. Percentages of rolling
cells were obtained by calculating the ratio of rolling cells and total cells
observed in the area of interest. Data presentation is based on the median
value of 10 vessels/3 mice per strain; Po0.05; n¼ 3. Statistical significance
was determined using analysis of variance multiple comparisons and
Bonferroni procedure. þ /þ wt mice, * and yPo0.05; n.s., not significant.
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DISCUSSION
DMF influences a variety of cell types and molecules
participating in inflammatory conditions. It induces expres-
sion of Th2 cytokines in keratinocyte/T-cell cocultures
(Ockenfels et al., 1998), inhibits keratinocyte proliferation
(Thio et al., 1994), and prevents differentiation of monocytes
into dendritic cells (Zhu and Mrowietz, 2001). Furthermore,
DMF leads to a reduction of cytotoxic T cells as well as
T-helper cells (Sebo¨k and Schneider, 2000), interferes with the
cellular glutathione metabolism, and shows immunosuppres-
sive effects (Nelson et al., 1999; Lehmann et al., 2007). Here,
we investigated the effect of DMF on adhesion molecule and
activation marker expression on CD3-positive T cells as
important effector cells in psoriasis. Superantigens, such as
TSST-1, belong to the strongest T-cell-activating compounds,
stimulating a large proportion of T cells, as compared with
nominal antigens, via their interaction with T-cell receptor
Vb-chains. Additionally, they have been shown to be involved
in the induction of psoriasis (Leung et al., 1995; Boehncke
et al., 1996, 1997). Also, TSST-1 significantly increases the
expression of CD25, CD69, HLA-DR, and CLA on CD3-
positive T cells (Zollner et al., 2002). Therefore, we used
TSST-1 as the activating stimulus. Additionally, we demon-
strated that non-toxic concentrations of DMF substantially
alter the expression of superantigen-induced activation
markers and adhesion molecules (Figure S1).
DMF caused a dose-dependent reduction of CD25 (IL-2R)
and HLA-DR, two activation markers that characterize an
early and late activation state of T cells, whereas surface
expression of CD69 was slightly increased by DMF. T cells
changing from a resting to an activated state during immune
response upregulate the synthesis of IL-2 and expression of
IL-2 receptors (Smith, 1988). Interaction of these leads to
cellular proliferation and emigration of effector cells. By
downregulating CD25, DMF seems to interrupt the contin-
uous production of proinflammatory immune cells, including
the differentiation into Th1 cells. CD69 as a negative
regulator of the immune response (Sancho et al., 2003) was
upregulated. In addition to the previously described direct
effects of DMF on inflammation, such as secretion of Th2
cytokines (de Jong et al., 1996), DMF may thus indirectly
counteract the proinflammatory condition by inducing anti-
inflammatory cytokines.
Lymphocyte extravasation is essential for efficient surveil-
lance of tissues for infectious pathogens and for the
recruitment of effector cells to sites of inflammation (von
Andrian and Mackay, 2000). E- and P-selectin are essential
molecules in the rolling process, the initial step of leukocyte
migration. In vivo studies showed that PSGL-1 interaction
with P-selectin is required for rolling of human leukocytes
(Moore et al., 1995; Norman et al., 1995). We therefore
investigated the effect of DMF on adhesion molecule
expression and binding. Increasing concentrations of DMF
dose-dependently inhibited the expression of CLA on the
surface of CD3-positive cells and caused a strong reduction
in binding to E-selectin, P-selectin, and VCAM-1, but did not
influence the expression of CD54 and PSGL-1 (CD162) on
CD3-positive cells.
Using intravital microscopy we showed that under
physiological conditions, TSST-1 treatment of cells strongly
increased rolling, whereas pre-treatment with DMF reduced
rolling to basal levels. This observation might be explained
by an inhibition of E- and P-selectin function, as indicated
by our in vitro data (Figure 1 and Table 1). In line with
this, both selectins contribute to leukocyte rolling in
non-inflamed murine skin venules, as shown by immuno-
histochemistry and functional studies. More specifically,
P-selectin controls rolling frequency, whereas E-selectin
dictates rolling velocity (Weninger et al., 2000). Because
DMF had no effect on the rolling of TSST-1-activated T cells
in P-selectin-deficient mice, and antibody-mediated block-
ade of E-selectin did not further reduce rolling, the in vivo
effects of DMF on leukocyte rolling seem to be primarily
P-selectin-dependent.
In summary, our findings add inhibition of leukocyte
rolling through modulation of adhesion molecule expression
to the list of DMF-mediated anti-inflammatory activities.
Since DMF affects molecules and processes of general
importance in the pathogenesis of inflammation, we expect
it to be clinically effective not only in psoriasis but in other
related inflammatory conditions as well. In line with this
perception, a second-generation fumarate, BG-12, showed
promising results in a clinical phase II trial in multiple
sclerosis (Press release (2006) http://www.biogenidec.com/
news/PR_129.pdf, accessed June 16, 2006).
MATERIALS AND METHODS
Mice
Male C57Bl/6 mice, aged 6-8 weeks, were purchased from Harlan
GmbH (Borchen, Germany). P-selectin-deficient (P/) mice
(B6.129S7-Selptm1Bay/J) on the C57Bl/6 background were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). Mice were
held on a 12 hour light/dark cycle at the animal facility of the J.W.
Goethe University. They were fed acidified drinking water and
standard chow ad libitum. Animal experiments were approved by
the governmental administration (Darmstadt, Germany).
Reagents
DMF was purchased from Merck (Darmstadt, Germany) and a stock
solution (10 mg/ml) was prepared in DMSO. Antibodies for the
detection of CLA, CD25, CD54, CD69, and HLA-DR were
purchased from Pharmingen (BD Biosciences, Heidelberg, Ger-
many) unless otherwise indicated. Binding of E-selectin, P-selectin,
and VCAM-1 was performed using chimera fusion proteins
purchased from R&D Systems (Wiesbaden, Germany).
Cell isolation and culture conditions
Human PBMCs were prepared by Ficoll–Hypaque density gradient
sedimentation (Pharmacia, Uppsala, Sweden) from buffy coats
obtained from the Department for Transfusion Medicine, Frankfurt,
and adjusted to 1 106 cells/ml in AIM-V cell culture medium (Life
Technologies, Paisley, UK). Cells were either left unstimulated or
activated using the TSST-1 (50 ng/ml) of Staphylococcus strains
(Sigma-Aldrich, Steinheim, Germany) as described previously (Zoll-
ner et al., 2002). The stock solution of DMF was diluted in medium
and treatment with 0.1, 1.0, 2.5, and 5.0mg/ml DMF was performed
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2 hours before TSST-1 activation. After 96 hours cells were harvested,
washed, and used for flow cytometry or intravital microscopy.
Flow cytometry
Surface expression. Cells were incubated for 30 minutes with
appropriate directly labeled antibodies, washed, and used for
analysis. All antibodies were purchased from BD Pharmingen
(Heidelberg, Germany) unless otherwise indicated. Expression was
analyzed using anti-CLA (HECA-452; BD Pharmingen, Heidelberg,
Germany), anti-CD25 (Clone B1.49.9; Immunotech, Krefeld, Ger-
many), anti-CD69 (clone TP1.55.3; Immunotech), anti-CD54 (clone
84H10; Immunotech), and anti-HLA-DR combined with anti-CD3
IgG. Appropriate isotype controls were used. Detection of PSGL-1
(CD162, clone 5D8.812; Immunotech) was investigated using anti-
CD162 followed by anti-mouse IgG (Dianova, Hamburg, Germany).
In vitro binding assay. Binding to E-selectin, P-selectin, and
VCAM-1 was tested using recombinant selectin-immunoglobulin
chimeras (40 mg/ml; R&D Systems). Fusion proteins and second
antibody (F(ab)2 anti-human IgG; Dianova) were incubated over-
night at 41C. Cells were then treated for 30 minutes with 1mg fusion
protein in Ca2þ /Mg2þ -containing phosphate-buffered saline at
room temperature. Thereafter, cells were washed and analyzed on
FACSCalibur using CellQuest Pro software. Staining with secondary
anti-human IgG served as isotype control. Propidium iodide staining
was always included into the experiments.
Intravital microscopy
Intravital microscopy was performed as recently described (Ludwig
et al., 2004): Unstimulated, TSST-1-treated, or TSST-1 plus
DMF-treated (0.1, 1, 2.5, and 5.0mg/ml) PBMCs were fluorescence
labeled using CFDA-SE (carboxyfluorescein diacetate succinimidyl
ester; Molecular Probes, Invitrogen, Karlsruhe, Germany), washed,
resuspended in fetal calf serum-free medium, and subsequently
injected downstream of the carotid artery into anesthetized C57Bl/6
mice. To study the influence of DMF on selectin-mediated rolling,
P-selectin-knockout mice were used. TSST-1-treated cells were
first injected for determination of basal rolling. After injection of
100mg isotype control (rat anti-mouse IgG, NA/LE, BD Pharmingen),
TSST-1 plus DMF-treated cells were applied and rolling was
documented. Finally, the effect of an anti-E-selectin antibody (anti-
CD62E, NA/LE; BD Pharmingen) was analyzed. For evaluation, cells
of at least three vessels per mouse were counted. The rolling fraction
corresponds to the ratio of rolling cells and total cells observed in the
area of interest.
Statistical analysis
All data are displayed as means7SEM. The data were analyzed
using Student’s t-test, and a Bonferroni correction was applied when
multiple comparisons were necessary. Po0.05 was deemed
significant. Statistics were performed using GraphPad Prism 4 or
SigmaStat.
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Figure S1. Propidium iodide staining of DMF-treated CD3-positive T cells.
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